PT  - JOURNAL ARTICLE
AU  - Righolt, Christiaan H.
AU  - Pabla, Gurpreet
AU  - Mahmud, Salaheddin M.
TI  - The epidemiology and direct medical costs of diseases associated with human papillomavirus infection among men in Manitoba, Canada
AID  - 10.1101/2020.12.02.20242891
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.12.02.20242891
4099  - http://medrxiv.org/content/early/2020/12/04/2020.12.02.20242891.short
4100  - http://medrxiv.org/content/early/2020/12/04/2020.12.02.20242891.full
AB  - Background There is little information on the economic burden of human papillomavirus-related diseases (HPV-RDs) among men. We used province-wide clinical, administrative and accounting databases to measure the direct medical costs of HPV infections in men in Manitoba (Canada).Methods We included all males aged 9 years and older with health insurance coverage in Manitoba between January 1997 and December 2016. We identified HPV-RD patient cohorts and matched each patient to HPV-RD-free men. We estimated the net direct medical cost (excess cost of hospitalizations, outpatient visits, and prescription drugs) of patients compared to their matches for anogenital warts (AGWs) and HPV-caused cancers. We adjusted costs to 2017 Canadian dollars. For each condition, we attributed costs to HPV based on the etiological fraction caused by HPV infection.Results We found that the median net direct medical cost was about $250 for AGW patients and $16,000 for invasive cancer patients. The total cost was about $49 million or $2.6 million per year. Overall, 54%-67% ($26-$33 million) was attributable to HPV infection according different estimates of the attributable fraction. The net annual attributable cost was $2.37-$2.95 per male resident and $161-$200 per male newborn. The estimated potential savings was 30% for the bivalent vaccine and 56%-60% for the quadrivalent and nonavalent vaccines.Conclusions Overall, HPV’s economic burden on males remains significant, the average cost of treating all conditions attributable to HPV was about $180 per male newborn. Invasive cancer accounted for the majority of these costs.Competing Interest StatementCHR has received an unrestricted research grant from Pfizer for an unrelated study. SMM has received unrestricted research grants from Merck, GlaxoSmithKline, Sanofi Pasteur, Pfizer and Roche-Assurex for unrelated studies. SMM has received fees as an advisory board member for Sanofi Pasteur. None of the other authors has any conflicts of interest to disclose.Funding StatementThis work was supported by the Merck Investigator Studies Program with a grant to the Biomedical Association of Manitoba (BAM). SMM's work is supported, in part, by funding from the Canada Research Chair Program. The sponsors had no role in the design or conduct of the study, including but not limited to, data identification, collection, management, analysis and interpretation, or preparation, review, or approval of the final results. The opinions presented in the report do not necessarily reflect those of the sponsors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the University of Manitoba Research Ethics Board (HS21956 (H2018:265)) and by MH's Health Information Privacy Committee (2018/2019-23).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used in this article was derived from administrative health and social data as a secondary use. The data was provided under specific data sharing agreements only for approved use at the Manitoba Centre for Health Policy (MCHP). The original source data is not owned by the researchers or MCHP and as such cannot be provided to a public repository. The original data source and approval for use has been noted in the acknowledgments of the article. Where necessary, source data specific to this article or project may be reviewed at MCHP with the consent of the original data providers, along with the required privacy and ethical review bodies.AGWanogenital wartCCMBCancerCare ManitobaCIScarcinoma in situDPINDrug Program Information NetworkEDemergency departmentEDISEmergency Department Information SystemHADHospital Abstracts DatabaseHPVhuman papillomavirusHPV-RDhuman papillomavirus-related diseaseMCHPManitoba Centre for Health PolicyMCRManitoba Cancer RegistryMHManitoba HealthMHPRManitoba Health Population RegistryMSDMedical Services DatabasePHINPersonal Health Identification NumberWRHAWinnipeg regional health authority